Journal Information
Vol. 19. Issue 7.
Pages 363-373 (August - September 2023)
Share
Share
Download PDF
More article options
ePub
Vol. 19. Issue 7.
Pages 363-373 (August - September 2023)
Original Article
Relationship between epicardial adipose tissue, systemic inflammatory diseases, and subclinical atheromatosis: A systematic review
Relación entre tejido adiposo epicárdico, enfermedades inflamatorias sistémicas y ateromatosis subclínica: una revisión sistemática
Walter Massona,b, Augusto Lavalle-Coboa,c, Leandro Barbagelatab, Martin Loboa,d, Juan Patricio Nogueirae,f,
Corresponding author
nogueirajuanpatricio@gmail.com

Corresponding author.
a Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology, Azcuenaga 980, Buenos Aires, Argentina
b Cardiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
c Cardiology Department, Sanatorio Finochietto, Av. Córdoba, 2678 Buenos Aires, Argentina
d Cardiology Department, Hospital Militar Campo de Mayo, Buenos Aires, Argentina
e Centro de Investigación en Endocrinología, Nutrición y Metabolismo (CIENM), Facultad de Ciencias de la Salud, Universidad Nacional de Formosa, Argentina
f Universidad del Pacifico, Asunción, Paraguay
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (3)
Table 1. Characteristics of the included observational studies.
Table 2. Epicardial adipose tissue in patients with chronic inflammatory diseases and controls.
Table 3. Main findings of the association between EAT and subclinical atheromatosis.
Show moreShow less
Abstract
Background and aims

Systemic inflammatory diseases could act as an unfavorable condition in which epicardial adipose tissue (EAT) becomes harmful to cardiovascular health. The objectives were: (a) to quantitatively compare the presence of EAT between patients with systemic inflammatory diseases and controls; (b) to analyze the association between EAT and subclinical atheromatosis in individuals with systemic inflammatory diseases.

Methods

Studies that have quantified EAT in a population with systemic inflammatory diseases compared to a control group, or that describe the association between EAT and the presence of subclinical atheromatosis in patients with systemic inflammatory diseases were included. A quantitative analysis was performed for the first objective. This systematic review was performed according to PRISMA guidelines.

Results

Twenty-one studies including 1448 patients with systemic inflammatory diseases, were considered eligible for this study. Patients with systemic inflammatory disease have a higher volume (MD: 10.4cm3 [1.8–19.1]; p<0.01), higher thickness (MD: 1.0mm [0.8–1.2]; p<0.01), and a statistically non-significant higher area (MD: 3.1cm2 [1.0–5.2]; p=0.46) of EAT compared to the control group. Most studies reported a significant association between EAT and subclinical atheromatosis in patients with different systemic inflammatory diseases.

Conclusion

This study demonstrated that EAT is increased in patients with systemic inflammatory diseases compared with healthy controls, and that EAT measurement is closely correlated with subclinical atherosclerosis in these patients. The causality of this association should be tested in prospective studies.

Keywords:
Epicardial adipose tissue
Systemic inflammatory diseases
Subclinical atheromatosis
Resumen
Objetivos

Las enfermedades inflamatorias sistémicas podrían aumentar el riesgo cardiovascular asociados a un aumento del tejido adiposo epicárdico (TAE). Los objetivos de este estudio, fueron: a) comparar cuantitativamente la presencia de TAE entre pacientes con enfermedades inflamatorias sistémicas y controles, y b) analizar la asociación entre TAE y atero“matosis subclínica en individuos con enfermedades inflamatorias sistémicas.

Métodos

Se incluyeron estudios que hayan cuantificado la TAE en una población con enfermedades inflamatorias sistémicas frente a un grupo control, o que describan la asociación entre la TEA y la presencia de ateromatosis subclínica en pacientes con enfermedades inflamatorias sistémicas. Para el primer objetivo se realizó un análisis cuantitativo. Esta revisión sistemática se realizó de acuerdo con las guías PRISMA.

Resultados

Veintiún estudios que incluyeron 1.448 pacientes con enfermedades inflamatorias sistémicas se consideraron elegibles para este estudio. Los pacientes con enfermedad inflamatoria sistémica tienen mayor volumen (DM: 10,4cm3 [1,8-19,1]; p<0,01), mayor grosor (DM: 1,0mm [0,8-1,2]; p<0,01) y un área mayor estadísticamente no significativa (DM: 3,1cm2 [1,0-5,2]; p=0,46) de EAT en comparación con el grupo de control. La mayoría de los estudios informaron una asociación significativa entre EAT y ateromatosis subclínica en pacientes con diferentes enfermedades inflamatorias sistémicas.

Conclusión

Este estudio demostró que la TAE aumenta en pacientes con enfermedades inflamatorias sistémicas en comparación con controles sanos, y que la medición de EAT está estrechamente relacionada con la aterosclerosis subclínica en estos pacientes. La causalidad de esta asociación debe probarse en estudios prospectivos.

Palabras clave:
Tejido adiposo epicárdico
Enfermedad inflamatoria sistémica
Ateromatosis subclínica

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?